21.78 USD
+0.1 (+0.46%)
SRZN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. While SRZN seems to be doing ok healthwise, there are quite some concerns on its profitability. SRZN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year SRZN has reported negative net income.
- In the past year SRZN has reported a negative cash flow from operations.
- In the past 5 years SRZN always reported negative net income.
- In the past 5 years SRZN always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -92.41%, SRZN is doing worse than 73.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -92.41% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-88.27%
ROA(5y)-71.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for SRZN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- SRZN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- SRZN has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for SRZN has been reduced compared to 5 years ago.
- There is no outstanding debt for SRZN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- SRZN has an Altman-Z score of -4.46. This is a bad value and indicates that SRZN is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of SRZN (-4.46) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.46 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- SRZN has a Current Ratio of 13.15. This indicates that SRZN is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 13.15, SRZN belongs to the top of the industry, outperforming 89.14% of the companies in the same industry.
- SRZN has a Quick Ratio of 13.15. This indicates that SRZN is financially healthy and has no problem in meeting its short term obligations.
- SRZN has a Quick ratio of 13.15. This is amongst the best in the industry. SRZN outperforms 89.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.15 | ||
| Quick Ratio | 13.15 |
3. Growth
3.1 Past
- The earnings per share for SRZN have decreased strongly by -110.16% in the last year.
- The Revenue for SRZN has decreased by -63.96% in the past year. This is quite bad
EPS 1Y (TTM)-110.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1800%
Revenue 1Y (TTM)-63.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-90.17%
3.2 Future
- Based on estimates for the next years, SRZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.05% on average per year.
- The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y21.3%
EPS Next 2Y31.09%
EPS Next 3Y20.41%
EPS Next 5Y10.05%
Revenue Next Year-31.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- SRZN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year SRZN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- SRZN's earnings are expected to grow with 20.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.09%
EPS Next 3Y20.41%
5. Dividend
5.1 Amount
- SRZN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SURROZEN INC / SRZN FAQ
What is the ChartMill fundamental rating of SURROZEN INC (SRZN) stock?
ChartMill assigns a fundamental rating of 2 / 10 to SRZN.
What is the valuation status of SURROZEN INC (SRZN) stock?
ChartMill assigns a valuation rating of 1 / 10 to SURROZEN INC (SRZN). This can be considered as Overvalued.
Can you provide the profitability details for SURROZEN INC?
SURROZEN INC (SRZN) has a profitability rating of 0 / 10.
Can you provide the financial health for SRZN stock?
The financial health rating of SURROZEN INC (SRZN) is 4 / 10.